Drugs / YUVA-GT-F801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03217032 | Jun 2025 → May 2027 expected | hemophilia A | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YUVA-GT-F801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03217032 ↗ |
| Action | Restore | “deliver a functional FVIII gene to overcome human clotting FVIII gene defect” NCT03217032 ↗ |